{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T02:20:15Z","timestamp":1792808415252,"version":"4.5.0"},"reference-count":19,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ejcancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Cancer"],"published-print":{"date-parts":[[2024,1]]},"DOI":"10.1016\/j.ejca.2023.113437","type":"journal-article","created":{"date-parts":[[2023,11,11]],"date-time":"2023-11-11T02:57:14Z","timestamp":1699671434000},"page":"113437","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":37,"special_numbering":"C","title":["Immunotherapy response in microsatellite stable metastatic colorectal cancer is influenced by site of metastases"],"prefix":"10.1016","volume":"196","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6554-5488","authenticated-orcid":false,"given":"Marwan","family":"Fakih","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chongkai","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3165-6286","authenticated-orcid":false,"given":"Jaideep","family":"Sandhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jian","family":"Ye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Colt","family":"Egelston","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaochen","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejca.2023.113437_bib1","doi-asserted-by":"crossref","first-page":"2509","DOI":"10.1056\/NEJMoa1500596","article-title":"PD-1 blockade in tumors with mismatch-repair deficiency","volume":"372","author":"Le","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejca.2023.113437_bib2","article-title":"Safety and antitumor activity of the anti-PD-1 antibody pembrolizumab in patients with advanced colorectal carcinoma","volume":"12","author":"O'Neil","year":"2017","journal-title":"PLOS One"},{"key":"10.1016\/j.ejca.2023.113437_bib3","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2016.34.15_suppl.3501","article-title":"Nivolumab \u00b1 ipilimumab in treatment (tx) of patients (pts) with metastatic colorectal cancer (mCRC) with and without high microsatellite instability (MSI-H): checkMate-142 interim results","volume":"34","author":"Overman","year":"2016","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2023.113437_bib4","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1158\/2326-6066.CIR-16-0325","article-title":"Liver metastasis and treatment outcome with anti-PD-1 monoclonal antibody in patients with melanoma and NSCLC","volume":"5","author":"Tumeh","year":"2017","journal-title":"Cancer Immunol Res"},{"key":"10.1016\/j.ejca.2023.113437_bib5","doi-asserted-by":"crossref","first-page":"1825","DOI":"10.1007\/s00262-018-2239-4","article-title":"Organ-specific response to nivolumab in patients with non-small cell lung cancer (NSCLC)","volume":"67","author":"Schmid","year":"2018","journal-title":"Cancer Immunol, Immunother"},{"key":"10.1016\/j.ejca.2023.113437_bib6","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2021.18416","article-title":"Clinical response to immunotherapy targeting programmed cell death receptor 1\/programmed cell death ligand 1 in patients with treatment-resistant microsatellite stable colorectal cancer with and without liver metastases","volume":"4","author":"Wang","year":"2021","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.ejca.2023.113437_bib7","doi-asserted-by":"crossref","first-page":"2053","DOI":"10.1200\/JCO.19.03296","article-title":"Regorafenib plus nivolumab in patients with advanced gastric or colorectal cancer: an open-label, dose-escalation, and dose-expansion phase Ib trial (REGONIVO, EPOC1603)","volume":"38","author":"Fukuoka","year":"2020","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2023.113437_bib8","doi-asserted-by":"crossref","first-page":"e1188","DOI":"10.1634\/theoncologist.2020-0161","article-title":"Regorafenib and nivolumab or pembrolizumab combination and circulating tumor DNA response assessment in refractory microsatellite stable colorectal cancer","volume":"25","author":"Wang","year":"2020","journal-title":"oncologist"},{"key":"10.1016\/j.ejca.2023.113437_bib9","doi-asserted-by":"crossref","first-page":"3560","DOI":"10.1200\/JCO.2021.39.15_suppl.3560","article-title":"Single-arm, phase 2 study of regorafenib plus nivolumab in patients with mismatch repair-proficient (pMMR)\/microsatellite stable (MSS) colorectal cancer (CRC)","volume":"39","author":"Fakih","year":"2021","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2023.113437_bib10","article-title":"Regorafenib plus toripalimab in patients with metastatic colorectal cancer: a phase Ib\/II clinical trial and gut microbiome analysis","volume":"2","author":"Wang","year":"2021","journal-title":"Cell Rep Med"},{"key":"10.1016\/j.ejca.2023.113437_bib11","doi-asserted-by":"crossref","DOI":"10.1016\/j.annonc.2023.04.014","article-title":"LBA-4 results from an expanded phase 1 trial of botensilimab (BOT), a multifunctional anti-CTLA-4, plus balstilimab (BAL; anti-PD-1) for metastatic heavily pretreated microsatellite stable colorectal cancer (MSS CRC)","volume":"34","author":"Bullock","year":"2023","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ejca.2023.113437_bib12","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2023.41.4_suppl.187","article-title":"Comparative analysis of tumor immune microenvironment in primary tumors vs metastatic tissue in microsatellite stable metastatic colorectal cancer","volume":"41","author":"Fakih","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2023.113437_bib13","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ejca.2023.113437_bib14","doi-asserted-by":"crossref","DOI":"10.1158\/1538-7445.AM2023-6676","article-title":"Abstract 6676: exploratory biomarker analyses in phase 1 study of regorafenib, ipilimumab, and nivolumab (RIN) in chemotherapy resistant microsatellite stable (MSS) metastatic colorectal cancer (mCRC)","volume":"83","author":"Ye","year":"2023","journal-title":"Cancer Res"},{"key":"10.1016\/j.ejca.2023.113437_bib15","doi-asserted-by":"crossref","DOI":"10.1126\/sciimmunol.aba0759","article-title":"Regulatory T cell control of systemic immunity and immunotherapy response in liver metastasis","volume":"5","author":"Lee","year":"2020","journal-title":"Sci Immunol"},{"key":"10.1016\/j.ejca.2023.113437_bib16","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1038\/s41591-020-1131-x","article-title":"Liver metastasis restrains immunotherapy efficacy via macrophage-mediated T cell elimination","volume":"27","author":"Yu","year":"2021","journal-title":"Nat Med"},{"key":"10.1016\/j.ejca.2023.113437_bib17","doi-asserted-by":"crossref","first-page":"1709","DOI":"10.1016\/S1470-2045(16)30500-9","article-title":"Prognosis of patients with peritoneal metastatic colorectal cancer given systemic therapy: an analysis of individual patient data from prospective randomised trials from the analysis and research in cancers of the digestive system (ARCAD) database","volume":"17","author":"Franko","year":"2016","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ejca.2023.113437_bib18","doi-asserted-by":"crossref","first-page":"3554","DOI":"10.1200\/JCO.2023.41.16_suppl.3554","article-title":"Prognostic value of liver metastases in colorectal cancer treated by systemic therapy: an ARCAD pooled analysis","volume":"41","author":"Cohen","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2023.113437_bib19","doi-asserted-by":"crossref","first-page":"2082","DOI":"10.1158\/2767-9764.CRC-23-0212","article-title":"Peritumoral immune-suppressive mechanisms impede intratumoral lymphocyte infiltration into colorectal cancer liver versus lung metastases","volume":"3","author":"Ye","year":"2023","journal-title":"Cancer Res Commun"}],"container-title":["European Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804923007396?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804923007396?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,17]],"date-time":"2025-10-17T20:42:05Z","timestamp":1760733725000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0959804923007396"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1]]},"references-count":19,"alternative-id":["S0959804923007396"],"URL":"https:\/\/doi.org\/10.1016\/j.ejca.2023.113437","relation":{},"ISSN":["0959-8049"],"issn-type":[{"value":"0959-8049","type":"print"}],"subject":[],"published":{"date-parts":[[2024,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Immunotherapy response in microsatellite stable metastatic colorectal cancer is influenced by site of metastases","name":"articletitle","label":"Article Title"},{"value":"European Journal of Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejca.2023.113437","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"113437"}}